PhRMA debuts new ads in Go Boldly campaign

PhRMA debuts new ads in Go Boldly campaign

PhRMA worked with WPP Health & Wellness and Young & Rubicam on creative for the ads.

Five things for pharma marketers to know: Wednesday, April 19, 2017

Five things for pharma marketers to know: Wednesday, April 19, 2017

Valeant gave $100,000 to patient group to address affordability of its drug; Omnicom reports 3% increase in specialty group revenue; Verily to study biometric data

In Merck video, woman says a cure is the greatest invention

In Merck video, woman says a cure is the greatest invention

The drugmaker's video asks people in New York and San Francisco about their ideas for great inventions.

J&J blames lower Xarelto and Invokana sales on payer pressure

J&J blames lower Xarelto and Invokana sales on payer pressure

The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.

Five things for pharma marketers to know: Tuesday, April 18, 2017

Five things for pharma marketers to know: Tuesday, April 18, 2017

Novartis gets Breakthrough designation for its CAR-T therapy; Duchesney continues working with Kardashian; new user-fee deal to speed up FDA approvals

Facing a competitive market, Synergy looks to stand out with unbranded emojis

Facing a competitive market, Synergy looks to stand out with unbranded emojis

The drugmaker hopes its emojis will raise awareness about treatment options for constipation.

SPONSORED: Using co-pay programs to acquire and engage patients

SPONSORED: Using co-pay programs to acquire and engage patients

Along with lower costs, effective co-pay offset programs boost patient adherence and better connect with doctors and pharmacies.

Five things for pharma marketers to know: Monday, April 17, 2017

Five things for pharma marketers to know: Monday, April 17, 2017

Kardashian West promotes Diclegis again; drugmakers are developing non-opioid painkillers; healthcare brands test Facebook Live

Some brands thought to shift online ad dollars, creating uncertainty for WebMD

Some brands thought to shift online ad dollars, creating uncertainty for WebMD

This and other changes in the market have created demand for new offerings, like mobile-friendly sites, video, and patient communities.

5 of healthcare's hardest nuts to crack

5 of healthcare's hardest nuts to crack

How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?

Regeneron uses VR to humanize retinal disease

Regeneron uses VR to humanize retinal disease

The drugmaker saw a gap in patient-physician conversation about retinal disease.

Five things for pharma marketers to know: Friday, April 14, 2017

Five things for pharma marketers to know: Friday, April 14, 2017

Lawmaker wants better enforcement of TV ads placed by lawyers; more toddlers are taking antipsychotics; Neurocrine puts off price disclosure of new drug

SPONSORED: Rebooting your approach to HUB services

SPONSORED: Rebooting your approach to HUB services

A trio of industry leaders counsels on numerous HUB strategies that will help providers vastly improve the patient experience.

Five things for pharma marketers to know: Thursday, April 13, 2017

Five things for pharma marketers to know: Thursday, April 13, 2017

Biogen licenses experimental Alzheimer's drug; Apple reportedly working on diabetes sensors; doc warns against industry payments

MM&M names winners of Young Jurists program

MM&M names winners of Young Jurists program

Meet Medela's Katie Busse, Intouch Solutions' Andrew Grojean, Heartbeat's Meghan Kate, Fingerpaint's Travis Rooke, and Havas Life Metro's Dan Sorine.

Five things for pharma marketers to know: Wednesday, April 12, 2017

Five things for pharma marketers to know: Wednesday, April 12, 2017

The FDA approves first drug to treat tardive dyskinesia; Americans use crowdfund sites to pay for prescriptions; stroke sufferers struggle with adherence

Genentech urges broader adoption of value-based payment models

Genentech urges broader adoption of value-based payment models

A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.

Off-label legal settlements do little to change prescribing patterns

Off-label legal settlements do little to change prescribing patterns

An analysis of claims data found that an off-label settlement for one Eli Lilly drug did not significantly change how often it was prescribed off-label after the settlements.

Large teaching hospitals more prone to breaches

Large teaching hospitals more prone to breaches

These facilities may be more prone to attack because there are more people at them with access to private patient data, whether to conduct medical research or educate new healthcare professionals.

Five things for pharma marketers to know: Tuesday, April 11, 2017

Five things for pharma marketers to know: Tuesday, April 11, 2017

Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer

Pacira, Trinity Health aim to address opioid use in surgeries

Pacira, Trinity Health aim to address opioid use in surgeries

Pacira also recently announced a partnership with Johnson & Johnson to co-promote its pain injection for certain surgeries.

Five things for pharma marketers to know: Monday, April 10, 2017

Five things for pharma marketers to know: Monday, April 10, 2017

Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose

Excedrin acts fast to ease Mets fan's headache

Excedrin acts fast to ease Mets fan's headache

Excedrin jumped at the chance to help relieve an angry fan's headache when he missed opening day of the New York Mets season due to train delays.

Hall of Femme of 2017

Hall of Femme of 2017

For the second year, MM&M is honoring 16 of the most-senior women in the healthcare industry.

Five things for pharma marketers to know: Friday, April 7, 2017

Five things for pharma marketers to know: Friday, April 7, 2017

The FDA rejected an outcomes update to the Januvia label; digital-health funding dropped in Q1 of 2017; the FDA approves 23andMe's genetic test

Gilead, Astellas also suspend ads on 'The O'Reilly Factor'

Gilead, Astellas also suspend ads on 'The O'Reilly Factor'

Bayer, Eli Lilly, GlaxoSmithKline, and Sanofi have suspended advertising on the show, according to news reports.

Five things for pharma marketers to know: Thursday, April 6, 2017

Five things for pharma marketers to know: Thursday, April 6, 2017

The FDA approves drugs faster than EMA; Botox goes to late-stage testing for depression; GSK recalls nearly 600,000 asthma inhalers

Analysis: Gender, racial diversity among CMOs shows little sign of progress

Analysis: Gender, racial diversity among CMOs shows little sign of progress

Several of the top-spending brands have never hired more than one female or non-white marketing boss, and some never have.

Five things for pharma marketers to know: Wednesday, April 5, 2017

Five things for pharma marketers to know: Wednesday, April 5, 2017

GSK pulls ads from "The O'Reilly Factor"; the FDA approves drug for Huntington's disease patients; lawmakers may remove pre-existing conditions requirement

How pharma marketers are using behavioral science

How pharma marketers are using behavioral science

A tool kit of pharma case studies and advice for healthcare brands in making behavioral science a foundational part of a marketing strategy.

Five things for pharma marketers to know: Tuesday, April 4, 2017

Five things for pharma marketers to know: Tuesday, April 4, 2017

Mylan allegedly increased EpiPen list price to appease PBMs; 20% of patients misdiagnosed by primary-care doctor: study; Mallinckrodt settles DEA probe

Top 40 Healthcare Transformers of 2017

Top 40 Healthcare Transformers of 2017

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts of 2017

Top 10 Innovation Catalysts of 2017

For the first time MM&M honors a group of 10 agency execs.

Five things for pharma marketers to know: Monday, April 3, 2017

Five things for pharma marketers to know: Monday, April 3, 2017

Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall

Humana navigates health insurance ups and downs

Humana navigates health insurance ups and downs

Tom Noland says protecting and enhancing Humana's reputation comes down to three things: corporate volunteerism, good media relations, and content creation.

Infographic: The physician view on patient data

Infographic: The physician view on patient data

A WebMD survey finds that patients are more engaged when they share their own health with their doctors.

Five things for pharma marketers to know: Friday, March 31, 2017

Five things for pharma marketers to know: Friday, March 31, 2017

Novartis ordered to turn over files about 80,000 speaking events; drugmakers set lower-than-expected prices at launch; funding goes to R&D of antibiotics

Cannes Lions announces pharma, health and wellness juries

Cannes Lions announces pharma, health and wellness juries

This year's festival will be held June 17 and 18.

Five things for pharma marketers to know: Thursday, March 30, 2016

Five things for pharma marketers to know: Thursday, March 30, 2016

Novartis CAR-T drug receives priority review; addiction center's ad compares addiction to cancer; Arizona passes off-label law

Drummy passes the torch at Heartbeat, moves to chairman role

Drummy passes the torch at Heartbeat, moves to chairman role

Agency vets Nadine Leonard and James Talerico to co-lead Publicis-owned shop.

Five things for pharma marketers to know: Wednesday, March 29, 2017

Five things for pharma marketers to know: Wednesday, March 29, 2017

A panel recommends the U.S. government license a hepatitis-C therapy; the FDA approves Roche MS drug; new eczema drug to cost $37,000 per year

Senate committee launches investigation into opioid marketing

Senate committee launches investigation into opioid marketing

The committee is seeking information about the companies' sales and marketing strategies.

What doctors have to say about those DTC ads

What doctors have to say about those DTC ads

We had SERMO, a social network for physicians, ask about 1,700 physicians what they have to say about the impact of DTC on patient care and choices. Note: It's not pretty.

The 2017 DTC Report: All the data in one place

The 2017 DTC Report: All the data in one place

Drugmakers again spent more on DTC advertising in 2016 than the year before.

Patients are taking on DTC ads. How will drugmakers respond?

Patients are taking on DTC ads. How will drugmakers respond?

Pharma spent more than $4 billion on TV ads last year. Empowered patient communities weren't impressed. Has DTC on TV reached its moment of reckoning?

Five things for pharma marketers to know: Tuesday, March 28, 2017

Five things for pharma marketers to know: Tuesday, March 28, 2017

Ovarian cancer drug nabs FDA approval; Senate committee to investigate opioid manufacturers; Allergan's acne drug reports positive Phase-III results

Veeva and QuintilesIMS tussle over customer reference data

Veeva and QuintilesIMS tussle over customer reference data

Veeva is countersuing QuintilesIMS in the wake of allegations that Veeva mishandled its proprietary data.

Five things for pharma marketers to know: Monday, March 27, 2017

Five things for pharma marketers to know: Monday, March 27, 2017

Alexion names former Baxalta head as CEO; U.S. dollar drops after AHCA-fail; EMA advises suspension of 300 generic drugs by Indian drugmaker

P&G exec who led Always #LikeAGirl campaign moves to comms leadership role at Novartis

P&G exec who led Always #LikeAGirl campaign moves to comms leadership role at Novartis

P&G's Mark Chakravarty has joined pharma giant Novartis in a senior role.

Pro Ad Report: All the data on medical journal spending in 2016

Pro Ad Report: All the data on medical journal spending in 2016

The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.

What five different pharma marketing careers look like

What five different pharma marketing careers look like

Five highly placed insiders in a range of roles and therapeutic categories share secrets to their success and advice that served them well along the way.

Five things for pharma marketers to know: Friday, March 24, 2017

Five things for pharma marketers to know: Friday, March 24, 2017

Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio

Five things for pharma marketers to know: Thursday, March 23, 2017

Five things for pharma marketers to know: Thursday, March 23, 2017

AHCA set for vote; J&J halts YouTube ads; approval decisions loom for Sanofi, Roche

Healthgrades' Eric Jensen on providing quality of life

Healthgrades' Eric Jensen on providing quality of life

Healthcare is sometimes about life or death, but is almost always about quality of life, says the EVP of health system products and strategy.

Read the complete March 2017 digital edition

Read the complete March 2017 digital edition

Here you'll find everything you need to know from MM&M's March 2017 issue, including our healthcare marketers trend report, our deep dive into orphan drugs, and more.

Roundtable: How healthcare agencies can retain and attract A-list talent

Roundtable: How healthcare agencies can retain and attract A-list talent

Seven execs from A-list agencies weigh in on talent acquisition and retention.

The 'i's have it for eye-care brand Xiidra

The 'i's have it for eye-care brand Xiidra

The Xiidra marketing team attempted to move away from the standard drug commercial to shine in a new market and challenge legacy techniques.

Five things for pharma marketers to know: Wednesday, March 22, 2017

Five things for pharma marketers to know: Wednesday, March 22, 2017

Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD

Top 25 respiratory brands, by sales

Top 25 respiratory brands, by sales

While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.

Novartis aims to bring first oral asthma drug to market in two decades

Novartis aims to bring first oral asthma drug to market in two decades

An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices

Five things for pharma marketers to know: Tuesday, March 21, 2017

Five things for pharma marketers to know: Tuesday, March 21, 2017

Eli Lilly claims it only realizes small percentage of list price increases; PBMs become latest target in pricing backlash; AHCA revised

Low-T DTC ads linked with more testing — and more prescriptions

Low-T DTC ads linked with more testing — and more prescriptions

Researchers found that DTC advertising was associated with significant increases in testing and treatment for these drugs

Five things for pharma marketers to know: Monday, March 20, 2017

Five things for pharma marketers to know: Monday, March 20, 2017

Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study

MM&M Startup Showdown connects startups with biopharma execs

MM&M Startup Showdown connects startups with biopharma execs

This program is designed to enable entrepreneurs and biopharma marketers to engage in an intelligent way to explore beyond-the-pill partnerships.

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.

New healthcare bill to negatively affect drugmakers: Moody's

New healthcare bill to negatively affect drugmakers: Moody's

Per the credit ratings agency, more uninsured Americans will lead to less demand for healthcare services and treatments.

Five things for pharma marketers to know: Friday, March 17, 2017

Five things for pharma marketers to know: Friday, March 17, 2017

The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug

Read the complete February 2017 digital edition

Read the complete February 2017 digital edition

Here you'll find everything you need to know from MM&M's February 2017 issue, including our payer state of the union, social media spotlight, and more.

Five things for pharma marketers to know: Thursday, March 16, 2017

Five things for pharma marketers to know: Thursday, March 16, 2017

Marathon to sell Emflaza to PTC Therapeutics; Emma Walmsley's salary is lower than Andrew Witty's; Trump considers Medicare negotiation of drug prices

Industry groups petition the FDA over off-label rule

Industry groups petition the FDA over off-label rule

PhRMA, BIO, and the Medical Information Working Group filed a citizen petition over a final rule they say raises risks for drugmakers.

Common joins Allergan campaign against vision loss

Common joins Allergan campaign against vision loss

Allergan's national vision-loss-prevention campaign, See America, has brought on rapper Common as a celebrity spokesman.

Five things for pharma marketers to know: Wednesday, March 15, 2017

Five things for pharma marketers to know: Wednesday, March 15, 2017

The FDA considers creating Office of Patient Affairs; Alexion to cut 7% of workforce; FDA committee votes against painkiller's benefits

Digital IDs become focus as drugmakers seek to track doctors' behavior online

Digital IDs become focus as drugmakers seek to track doctors' behavior online

Organizations are focusing on better ways to verify HCPs' digital identities.

Five things for pharma marketers to know: Tuesday, March 14, 2017

Five things for pharma marketers to know: Tuesday, March 14, 2017

Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices

Monday at SXSW: That's a wrap

Monday at SXSW: That's a wrap

SXSW's health track finally got a seat at the big-kids table.

Five things for pharma marketers to know: Monday, March 13, 2017

Five things for pharma marketers to know: Monday, March 13, 2017

Repatha reduces need for time-consuming procedure; Trump selects Gottlieb to lead the FDA; Acorda launches Alexa skill for MS

Sunday at SXSW: Healthcare costs and cancer

Sunday at SXSW: Healthcare costs and cancer

A high-profile cancer track commands attention, while wearables and IBM Watson Health come under fire.

Saturday at SXSW: Hooray for health

Saturday at SXSW: Hooray for health

The first days at SXSW Health went deep on entrepreneurship and the marketing thereof.

MM&M conference to explore beyond-the-pill

MM&M conference to explore beyond-the-pill

The MM&M Transforming Healthcare Conference will be held May 1 in New York City.

Five things for pharma marketers to know: Friday, March 10, 2017

Five things for pharma marketers to know: Friday, March 10, 2017

Novartis' Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit

Havas combines Havas Health, Havas consumer health practices into new entity

Havas combines Havas Health, Havas consumer health practices into new entity

The organization is now called Havas Health & You and continues to be led by Donna Murphy.

Five things for pharma marketers to know: Thursday, March 9, 2017

Five things for pharma marketers to know: Thursday, March 9, 2017

Companies form alliance to lower healthcare costs; the EMA cautions doctors on switching patients to biosimilars; analyst says Remicade suit may be settled

Klara's Simon Lorenz on breaking away from the physician lifestyle

Klara's Simon Lorenz on breaking away from the physician lifestyle

He instead decided to find a way to make a physician's job easier by creating a clinical messaging platform.

MM&M's 2017 Agency A-to-Z survey is open

MM&M's 2017 Agency A-to-Z survey is open

The results will be compiled in MM&M's 2017 Agency A-to-Z Directory, the industry's most comprehensive list of healthcare marketing and advertising agencies.

Five things for pharma marketers to know: Wednesday, March 8, 2017

Five things for pharma marketers to know: Wednesday, March 8, 2017

Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs

Some CME experts remain skeptical when it comes to social media

Some CME experts remain skeptical when it comes to social media

There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.

Doctors seek more transparency from drugmakers: ePharma panel

Doctors seek more transparency from drugmakers: ePharma panel

Pharmaceutical companies often blur the lines between a drug's risks and benefits in ads, and that frustrates physicians.

Five things for pharma marketers to know: Tuesday, March 7, 2017

Five things for pharma marketers to know: Tuesday, March 7, 2017

GOP unveils ACA replacement; Trump is working on new drug-pricing system; researchers to study thousands of immunotherapies

Infographic: What's next for the point of care market

Infographic: What's next for the point of care market

About 30% of patients are more likely to fill a prescription after being exposed to healthcare ads at the point of care, according to Kantar Media.

Amgen launches new Repatha DTC ad

Amgen launches new Repatha DTC ad

The new spot for its cholesterol-lowering injection debuted last week.

Five things for pharma marketers to know: Monday, March 6, 2017

Five things for pharma marketers to know: Monday, March 6, 2017

Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema

Drugmakers again boost DTC spending, to $5.6 billion in 2016

Drugmakers again boost DTC spending, to $5.6 billion in 2016

Pfizer and Bristol-Myers Squibb were the top spenders last year.

Five things for pharma marketers to know: Friday, March 3, 2017

Five things for pharma marketers to know: Friday, March 3, 2017

Linzess prescriptions increased after new DTC ads; new ACA draft is hidden from lawmakers; Roche's breast-cancer combo drug reports positive results

Five things for pharma marketers to know: Thursday, March 2, 2017

Five things for pharma marketers to know: Thursday, March 2, 2017

Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project

2017 Healthcare Marketers Trend Report: All the data in one place

2017 Healthcare Marketers Trend Report: All the data in one place

The data stems from the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.

Why Philips' Erik Hollander turned to reinvention

Why Philips' Erik Hollander turned to reinvention

He describes his current charge as "transforming a more creative occupation into a science."

Five things for pharma marketers to know: Wednesday, March 1, 2017

Five things for pharma marketers to know: Wednesday, March 1, 2017

Trump reiterates call to bring down drug prices; Novartis renews its focus on immunotherapies; a new bill would allow drugs to be imported

MM&M's top 5 stories in February 2017

MM&M's top 5 stories in February 2017

WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram

Valeant beefs up Salix salesforce, to relaunch Addyi

Valeant beefs up Salix salesforce, to relaunch Addyi

Valeant added 250 primary care sales reps to promote its Salix portfolio.

Opinion

Newsletters

MM&M's T40

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.